CSL Limited
Research CSL Limited (CSJ) on Bullrun: market cap EUR 31.33B, P/E 12.3, dividend yield 3.9%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCSJ
- ExchangeF
- CountryAustralia
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 31.33B
- P/E12.3
- Dividend yield3.9%
- Financial periodQ4 2024
- RevenueEUR 8.21B
- Net incomeEUR 2.01B
- Free cash flowEUR 726.00M
- Gross margin52.1%
Valuation Snapshot
latest market cap is EUR 31.33B; P/E is 12.3; dividend yield is 3.9%.
About CSL Limited
CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants.
Frequently asked questions
What is CSL Limited's market cap?
CSL Limited's market capitalization is EUR 31.33B.
What is CSL Limited's P/E ratio?
CSL Limited's price-to-earnings (P/E) ratio is 12.3.
Does CSL Limited pay a dividend?
CSL Limited has a dividend yield of 3.9%.
What does CSL Limited do?
CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally.